Navigation Links
Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Date:11/18/2009

in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com or www.personalizedcancertreatment.com.

About Yale University

Founded in 1701, Yale University comprises three major academic components: Yale College (the undergraduate program), the Graduate School of Arts and Sciences, and the professional schools. In addition, Yale encompasses a wide array of centers and programs, libraries, museums, and administrative support offices. Approximately 11,250 students attend Yale. Founded in 1810, Yale School of Medicine is a world-renowned center for biomedical research, education and advanced healthcare. Among its 27 departments are one of the nation's oldest schools of public health and the internationally recognized Child Study Center, founded in 1911. Yale School of Medicine consistently ranks among the handful of leading recipients of research funding from the Nation
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
2. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
5. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
6. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
7. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
8. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
9. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
10. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... that it has been granted a patent by ... its unique delivery system for delivering its "original" ... for the treatment of diseases with an inflammatory ...
(Date:9/17/2014)... Cary, N.C. (PRWEB) September 17, 2014 ... solutions that advances science and healthcare, has renewed its ... term. , As part of the agreement, Personify will ... with a sustained emphasis on recruitment analytics, including time-to-fill, ... decision to renew our agreement with Personify was based ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... France, October 13 ,Following fulfillment of all the ... all outstanding shares of Satisloh Holding,AG, the world ... and markets antireflective coating units and surfacing,machines, as ... million in revenue in 2007 and employs more ...
... 12 Mentice, Inc., a,leading developer and ... systems and Education Management Solutions, Inc. (EMS), ... software solutions, today,announced at the Transcatheter Cardiovascular ... that enables Mentice to market,MenticeSIM(TM) as a ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... with the NASDAQ Listing Qualifications Panel to present ... 4450(b)(1)(A),which requires a minimum market value of listed ... Letter from The NASDAQ Stock Market LLC,on October ...
Cached Biology Technology:Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 2Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 3Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 3
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... September, 2014)More than $100 trillion in cumulative public ... carbon dioxide (CO2)a 40 percent reduction of urban ... the world expands public transportation, walking and cycling ... by the University of California, Davis, and the ... , Further, an estimated 1.4 million early deaths ...
(Date:9/16/2014)... Ore. -- Each tree species has its own bacterial ... and colleagues from other institutions who studied the genetic ... on a Panamanian island. , "This study demonstrates for ... families and with different ecological strategies possess very different ... W. Kembel, a former postdoctoral researcher in the UO,s ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2
... up a large fraction of known plant viruses and ... to crop plants throughout the world. New details of ... by scientists using a variety of sophisticated imaging techniques ... and collaborating institutions. These findings, just published in ...
... GSK company focused on discovering and developing small molecule ... 2 Diabetes, announced today that it published a new ... and its potential to treat diseases of aging such ... heart disease. Entitled "SIRTUINS Novel Therapeutic Targets ...
... articles that will be published in the October 2008 ... Community Ecology: A Hybrid Beast with a Molecular Master. ... Thomas D. Bruns. , DNA-based techniques have in recent ... the first time. Results show extremely high diversity and ...
Cached Biology News:Structures of important plant viruses determined 2Structures of important plant viruses determined 3Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery 2BioScience tip sheet, October 2008 2BioScience tip sheet, October 2008 3
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
LTBP-1 (E-20)...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: